palmidrol has been researched along with Schizophrenia in 5 studies
palmidrol: a cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection
palmitoyl ethanolamide : An N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This 8-week (trial timepoints: baseline, week 4, week 8), double-blind, placebo-controlled clinical trial randomized patients with schizophrenia in a 1:1 ratio to compare the efficacy and safety of 600 mg twice a day of PEA and matched placebo alongside a stable dose of risperidone." | 9.51 | Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial. ( Akhondzadeh, S; Bagheri, S; Khodaei Ardakani, MR; Moradi, K; Namaei, P; Salehi, A; TaghaviZanjani, F, 2022) |
| "In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the antimitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively." | 7.91 | Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. ( Babinska, Z; Bari, M; D'Addario, C; Di Bartolomeo, M; Di Marco, R; Di Marzo, V; Drago, F; Drazanova, E; Giurdanella, G; Iannotti, FA; Maccarrone, M; Mechoulam, R; Micale, V; Pekarik, V; Piscitelli, F; Ruda-Kucerova, J; Salomone, S; Starcuk, Z; Stark, T; Sulcova, A; Wotjak, CT, 2019) |
| "This 8-week (trial timepoints: baseline, week 4, week 8), double-blind, placebo-controlled clinical trial randomized patients with schizophrenia in a 1:1 ratio to compare the efficacy and safety of 600 mg twice a day of PEA and matched placebo alongside a stable dose of risperidone." | 5.51 | Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial. ( Akhondzadeh, S; Bagheri, S; Khodaei Ardakani, MR; Moradi, K; Namaei, P; Salehi, A; TaghaviZanjani, F, 2022) |
| "We analyzed plasma concentrations of anandamide, 2-arachidonoyl-sn-glycerol, palmitoylethanolamide and oleoylethanolamide from 25 twin pairs discordant for schizophrenia, six discordant for bipolar disorder and eight healthy twin pairs to determine hereditary traits." | 3.91 | Familial abnormalities of endocannabinoid signaling in schizophrenia. ( Hellmich, M; Koethe, D; Leweke, FM; Meyer-Lindenberg, A; Mueller, JK; Pahlisch, F; Piomelli, D; Rohleder, C; Torrey, EF, 2019) |
| "In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the antimitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively." | 3.91 | Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. ( Babinska, Z; Bari, M; D'Addario, C; Di Bartolomeo, M; Di Marco, R; Di Marzo, V; Drago, F; Drazanova, E; Giurdanella, G; Iannotti, FA; Maccarrone, M; Mechoulam, R; Micale, V; Pekarik, V; Piscitelli, F; Ruda-Kucerova, J; Salomone, S; Starcuk, Z; Stark, T; Sulcova, A; Wotjak, CT, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salehi, A | 1 |
| Namaei, P | 1 |
| TaghaviZanjani, F | 1 |
| Bagheri, S | 1 |
| Moradi, K | 1 |
| Khodaei Ardakani, MR | 1 |
| Akhondzadeh, S | 1 |
| Koethe, D | 2 |
| Pahlisch, F | 2 |
| Hellmich, M | 2 |
| Rohleder, C | 1 |
| Mueller, JK | 1 |
| Meyer-Lindenberg, A | 1 |
| Torrey, EF | 1 |
| Piomelli, D | 3 |
| Leweke, FM | 3 |
| Stark, T | 1 |
| Ruda-Kucerova, J | 1 |
| Iannotti, FA | 1 |
| D'Addario, C | 1 |
| Di Marco, R | 1 |
| Pekarik, V | 1 |
| Drazanova, E | 1 |
| Piscitelli, F | 1 |
| Bari, M | 1 |
| Babinska, Z | 1 |
| Giurdanella, G | 1 |
| Di Bartolomeo, M | 1 |
| Salomone, S | 1 |
| Sulcova, A | 1 |
| Maccarrone, M | 1 |
| Wotjak, CT | 1 |
| Starcuk, Z | 1 |
| Drago, F | 1 |
| Mechoulam, R | 1 |
| Di Marzo, V | 1 |
| Micale, V | 1 |
| Muhl, D | 1 |
| Gerth, CW | 1 |
| Hoyer, C | 1 |
| Klosterkötter, J | 1 |
| Giuffrida, A | 1 |
| Wurster, U | 1 |
| Emrich, HM | 1 |
2 trials available for palmidrol and Schizophrenia
| Article | Year |
|---|---|
Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial.
Topics: Amides; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Drug Therapy, Combination | 2022 |
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
Topics: Acute Disease; Adult; Amides; Amisulpride; Antipsychotic Agents; Arachidonic Acids; Cannabidiol; Dou | 2012 |
3 other studies available for palmidrol and Schizophrenia
| Article | Year |
|---|---|
Familial abnormalities of endocannabinoid signaling in schizophrenia.
Topics: Adult; Amides; Arachidonic Acids; Bipolar Disorder; Endocannabinoids; Ethanolamines; Female; Genetic | 2019 |
Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia.
Topics: Amides; Animals; Arachidonic Acids; Cannabidiol; Disease Models, Animal; Endocannabinoids; Ethanolam | 2019 |
Elevated endogenous cannabinoids in schizophrenia.
Topics: Adult; Amides; Arachidonic Acids; Cannabinoids; Chromatography, High Pressure Liquid; Endocannabinoi | 1999 |